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Cardiac gene therapy has emerged as a promising 
option to treat advanced heart failure (HF). Advances in 
molecular biology and gene targeting approaches are 
offering further novel options for genetic manipulation 
of the cardiovascular system. The aim of this study was 
to improve cardiac function in chronic HF by overex-
pressing constitutively active inhibitor-1 (I-1c) using a 
novel cardiotropic vector generated by capsid reengi-
neering of adeno-associated virus (BNP116). One month 
after a large anterior myocardial infarction, 20 Yorkshire 
pigs randomly received intracoronary injection of either 
high-dose BNP116.I-1c (1.0 × 1013 vector genomes (vg), 
n = 7), low-dose BNP116.I-1c (3.0 × 1012 vg, n = 7), or 
saline (n = 6). Compared to baseline, mean left ventricu-
lar ejection fraction increased by 5.7% in the high-dose 
group, and by 5.2% in the low-dose group, whereas it 
decreased by 7% in the saline group. Additionally, pre-
load-recruitable stroke work obtained from pressure–vol-
ume analysis demonstrated significantly higher cardiac 
performance in the high-dose group. Likewise, other 
hemodynamic parameters, including stroke volume and 
contractility index indicated improved cardiac func-
tion after the I-1c gene transfer. Furthermore, BNP116 
showed a favorable gene expression pattern for target-
ing the heart. In summary, I-1c overexpression using 
BNP116 improves cardiac function in a clinically relevant 
model of ischemic HF.
Received 1 March 2014; accepted 3 July 2014; advance online  
publication 2 September 2014. doi:10.1038/mt.2014.127
INTRODUCTION
Significant progresses in treatment of acute cardiac diseases, 
including acute myocardial infarction (MI) and decompensated 
heart failure (HF), have increased survival rates dramatically. 
However, patients who survive the acute phase suffer from 
chronic HF, and population studies show growing numbers of 
this demographic.1 Despite the improved care for these patients, 
mortality of chronic HF is high and remains to be the main 
cause of death in the developed world.1 The primary course of 
rescue for these patients continues to be cardiac transplanta-
tion. However, this choice suffers from a lack of sufficient organ 
supply and is highly invasive. Together with an aging popula-
tion, application of cardiac transplant will be highly limited, 
and alternative treatments with less invasive and widely appli-
cable means are needed.
Gene therapy is emerging as a promising therapeutic 
approach for treating chronic HF, supported by a growing num-
ber of positive preclinical studies2 and a recent successful result 
in a phase 2 study (CUPID trial) targeting the cardiac sarcoplas-
mic/endoplasmic reticulum Ca2+ ATPase pump (SERCA2a).3 The 
appropriate combination of vector and gene are key for success-
ful gene therapy, and advances in understanding the molecular 
mechanisms offer several therapeutic options.4 Adeno-associated 
virus (AAV) is the vector selected for the CUPID trial and has 
the advantage of being nonpathogenic, having a long expres-
sion profile compared to other viral vectors such as adenovirus.5 
However, a reduced efficacy in patients with high neutralizing 
antibody (NAb) titers to AAV has been demonstrated, limit-
ing the broad application of this approach for all the patients.6 
Recently, “biological nanoparticles” designed to mimic key physi-
cochemical properties of virion shells with cardiotropism were 
developed using capsid reengineering techniques.7 Of particular 
interest, a chimeric vector of AAV-2 and 8 (BNP116) displayed 
predominant muscle tropism together with an altered antigenic 
profile8 and thus holds significant promise for cardiac targeting 
while altering the antigenicity. Although a mouse study dem-
onstrated high transduction in the heart and markedly reduced 
off-target expression in the major organs,8 the efficacy in more 
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HF may result from multiple causes, but defective cardiac Ca2+ 
homeostasis is an important final common pathway.9,10 We have 
recently reported that AAV-9 mediated overexpression of con-
stitutively active inhibitor-1 (I-1c), a potential target for cardiac 
gene transfer, can preserve cardiac function in a swine model of 
ischemic HF.11 Our goals in this study were (i) to establish the util-
ity of a novel cardiotropic vector, BNP116, for cardiac gene trans-
fer in a clinically relevant animal model, and (ii) to demonstrate 
further the efficacy of I-1c in a large animal model of ischemic 
HF. BNP116 was developed as a chimera of AAV-2/AAV-8, which 
readily traverses the blood vasculature and selectively transduces 
cardiac and whole-body skeletal muscle tissues with high effi-
ciency while detargeting the liver and the lungs.8
RESULTS
One month after MI, pigs developed chronic HF as evidenced by 
impaired cardiac function with left ventricular (LV) dilation (end 
diastolic volume: 40.8 ± 5.7 ml versus 81.7 ± 17.3 ml, P < 0.001, end 
systolic volume: 12.1 ± 2.8 ml versus 49.9 ± 15.0 ml, P < 0.001, LV 
ejection fraction (EF): 70.5 ± 3.6% versus 39.9 ± 6.8%, P < 0.001, 
before MI versus 1 month post-MI, respectively). A total of 20 
pigs were randomized to receive high-dose BNP116.I-1c (high-
dose group; 1.0 × 1013 vector genomes (vg), n = 7), low-dose 
BNP116.I-1c (low-dose group; 3.0 × 1012 vg, n = 7), or saline (con-
trol group, n = 6). Due to the relatively high prevalence of NAb to 
BNP116 in pigs, all animals with NAb titers <1:8 were included 
in either the high-dose or low-dose groups and not in the control 
group. Randomization was performed to match baseline charac-
teristics between the groups with priority between the high-dose 
group and the control group. One pig each in the high-dose and 
the low-dose group died within 24 hours after the injection. The 
cause of deaths was uncertain, but no signs of recent infarction 
were found in postmortem  examination. One pig in the control 
group was excluded due to the severe cardiac depression at 3 
months due to vascular puncture induced intrathoracic bleeding.
Cardiac function and volumes
Cardiac function and volumes were evaluated with a high-
fidelity conductance catheter, Swan-Ganz catheter, and blinded 
three dimensional echocardiography (3DE) analyses (Figure 1). 
Excellent 3DE reproducibility allowed us to evaluate accurately 
the post-MI LV dilatation. Intra- and interobserver intraclass 
correlation for LV volumes were 0.99 (P < 0.001) and 0.93 (P < 
0.001), respectively. Before gene transfer, functional and volu-
metric parameters were similar between the high-dose and the 
control groups. However, the low-dose group tended to have a 
better function and smaller volumes with statistically different 
stroke volumes from the control group (Table 1). In the control 
group, average of relative changes to the baseline in mean LVEF 
was –7% while both end diastolic volume and end systolic volume 
increased about 40% during the 2 months between gene delivery 
and follow-up. In contrast, gene transfer of I-1c improved LVEF 
by an average of 5.7% in the high-dose group and by 5.2% in the 
low-dose group without statistical significance (P = 0.23 and P = 
0.27, respectively) and suppressed LV dilatation (Figure 2). LV 
end diastolic volume and LV end systolic volume changes were 
significantly lower in the low-dose group compared to the control 
group. Other hemodynamic parameters consistently indicated 
improved cardiac function after the gene transfer (Figure 2). It 
is notable that the high-dose group had significantly increased 
stroke volume while preload-recruitable stroke work was also 
increased, indicating that it was not due to the alteration in after-
load, but to the improved cardiac performance. Consistent with 
the LV volumes, heart weights and scar sizes were smaller in the 
groups that received gene therapy (Figure 3).
I-1c distribution
mRNA levels of I-1c in the heart remote to the scar was low and 
required relatively high numbers of cycles to be detected by real-
time quantitative polymerase chain reaction. I-1c mRNA levels 
in the brain, liver, lung, and kidney were compared to the pigs 
who received AAV-9.I-1c from the previously published study11 
by relative quantitation to the heart in individual animals. Lung 
was the major organ with extra cardiac gene expression followed 
by the liver (Figure 4). Only one pig each in the AAV-9 and 
BNP116 high-dose groups had detectable copies of I-1c mRNA 
in the brain, and no pigs had detectable levels of I-1c genome in 
the kidney. Accurate quantitation of I-1c mRNA levels may not be 
possible due to the low mRNA level, however, the BNP116 group 
seemed to have similar to lower levels of off-target gene expres-
sion relative to the AAV-9 group. Histological analyses of major 
organs revealed no significant changes due to BNP116.I1c injec-
tion (Supplementary Figure S1). Cardiac transduction efficiency 
was also evaluated by injection of BNP116.green fluorescent pro-
tein (GFP) in four pigs and it was similar to AAV-9.GFP (n = 3) (% 
green fluorescent myocytes at the anterior wall: 64.2 ± 9.3% versus 
63.0 ± 9.5%, P = 0.86).
Prevalence of NAb in pig and human sera
Of the 66 pigs analyzed for NAb against BNP116 in this study, only 
9% had inhibitory titers of less than 1:2. Due to the relatively high 
prevalence of NAbs against BNP116, we included pigs with NAb 
titers up to less than 1:8. To evaluate the clinical utility of this vec-
tor, the prevalence of NAb to BNP116 in the human population 
was investigated in sera from 31 different individuals. Although 
the seroprevalence of more than 1:8 was higher in humans, those 
with NAb titers of less than 1:2 were also more prevalent in human 
compared to the pigs (Figure 5).
DISCUSSION
In this study, we demonstrated that BNP116.I-1c gene transfer 
improves cardiac function and possibly prevents post-MI LV 
dilatation in a well-established model of chronic ischemic cardio-
myopathy. The beneficial impact of I-1c gene transfer on cardiac 
function was revalidated in the most clinically relevant model 
together with a promising capability of a novel vector for clinical 
application. Furthermore, the intracoronary delivery route used 
in this study is readily available in the clinical practice, and the less 
invasive nature offers potential benefit over other delivery meth-
ods for patients with severe HF.
I-1c as a therapeutic tool
Aberrant calcium handling is a consistent finding in fail-
ing hearts in human and experimental studies.9,10 Several key 
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molecules have been shown to be responsible for the abnormal 
calcium cycling.4 Among them, the SERCA2a/phospholamban 
complex plays a pivotal role in mediating intracellular calcium 
homeostasis, and decreased SERCA2a activity is strongly asso-
ciated with HF regardless of etiology.4 Inhibitor-1 (I-1) is one 
of the SERCA2a/phospholamban-complex upstream regula-
tors, which is also closely linked to the β-adrenoceptor system.12 
Upon phosphorylation of the Thr35 site by PKA, I-1 suppresses 
protein phosphatase-1 (PP-1) activity, thereby maintaining 
higher phospholamban phosphorylation and leads to increased 
SERCA2a activity.12,13 I-1 expression as well as phosphorylation 
of I-1 Thr35 are shown to be decreased in HF together with 
increased PP-1 activity.14–16 Heart-specific overexpression of I-1 
showed detrimental effects on cardiac function in mice, and it 
was accompanied by increased PP-1 levels.17 This may be due 
to the overall effect of phosphorylation at other sites such as I-1 
Ser6718 and Thr7519 which are shown to result in increased PP-1 
activity. The rational for overexpressing I-1c is that it is truncated 
to 65 amino acids from 171 and lacks other phosphorylation 
sites that negatively impact cardiac function. In addition, Thr 35 
is replaced by phosphomimetic asparatic acid (T35D) and takes 
constitutively active form, thus leading to decreased PP-1 activ-
ity. In fact, several studies showed potential therapeutic benefit 
of I-1c on HF in experimental animal studies.11,20–22 Our study 
is consistent with these results and further confirms the efficacy 
of I-1c overexpression. As was the case in the AAV-9.I-1c gene 
transfer,11 the level of I-1c detected in the heart was relatively 
low. However, the level of I-1 protein in the heart is originally 
low,13 and we have previously shown that a similar level of I-1c 
expression is sufficient to positively influence cardiac function.11 
Due to the higher variability than we expected, we were not able 
to show statistically significant improvement in LVEF after gene 
transfer. While our study may have been underpowered to show 
improvement in LVEF as an endpoint, we have demonstrated 
improvements in multiple functional parameters suggesting a 
favorable effect of I-1c gene transfer on post-MI heart. Although 
dP/dt maximum showed similar changes between the high-dose 
and control groups, the load dependence of this parameter has 
been well recognized23 and, when normalized with isovolumic 
developed pressure, the improvement in contractitliy index 
was significant in the high-dose group. Moreover, preload-
recruitable stroke work is the established parameter of load 
Figure 1  Representative three dimensional echocardiography (3DE) analysis of left ventricular volumes and ejection fraction. Representative 
color 3DE movies from each group are provided in Supplementary Material (Supplementary Movies S1–S3). EDV, end diastolic volume; EF, 
ejection fraction; ESV, end systolic volume; SV, stroke volume.
EDV = 98.0 ml
ESV = 52.3 ml
Tmsv Sel-SD = ****
Tmsv Sel-Dif = ****
Tmsv Sel-SD = ****
EF = 46.7 %
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independent measures of LV contractility,23,24 and improvement 
in this parameter was found after high-dose BNP116.I-1c gene 
transfer. We saw a significantly lower LV volume increase in only 
the low-dose group. In addition, scar size at 3 months was sig-
nificantly smaller in the low-dose group compared to control. 
Although there may be an inhibitory effect of scar expansion 
Table 1 Left ventricular characteristics before and after gene transfer
Baseline Two months post-gene transfer
Control 





(1.0 × 1013 vg;  
n = 6)
Control 







BW (kg) 25.1 ± 0.8 24.2 ± 1.0 25.2 ± 2.0 36.1 ± 2.4* 35.0 ± 2.6 37.7 ± 2.8
3D echocardiography
  EF (%) 37.2 ± 4.0 43.3 ± 6.9 38.8 ± 7.7 34.5 ± 6.3 45.5 ± 10.1 40.4 ± 6.2
  EDV (ml) 82.8 ± 22.6 76.0 ± 19.0 84.2 ± 11.2 114.8 ± 26.9 92.4 ± 19.4 112.3 ± 24.7
  ESV (ml) 52.7 ± 18.3 43.9 ± 14.9 51.9 ± 12.2 75.8 ± 22.0 51.2 ± 18.5 67.9 ± 22.4
Pressure catheter
  LVPmax (mmHg) 104 ± 12 106 ± 22 106 ± 16 123 ± 14 140 ± 27 121 ± 16
  dP/dt max (mmHg/second) 1,478 ± 241 1,567 ± 380 1,483 ± 409 1,656 ± 419 1,891 ± 252 1,657 ± 506
  Contractility index (1/second) 42.1 ± 6.9 40.2 ± 11.9 32.9 ± 6.5 31.6 ± 9.0 31.2 ± 4.3 33.8 ± 4.1
  dP/dt min (mmHg/second) −1,473 ± 450 −1,232 ± 470 −1,315 ± 316 −2,239 ± 781 −1,993 ± 501 −1,610 ± 487
  Tau (ms) 69.0 ± 17.4 86.7 ± 31.2 78.2 ± 13.6 66.3 ± 10.1 62.4 ± 11.1 71.1 ± 11.3
  HR (bpm) 70.5 ± 13.0 54.2 ± 11.3 60.2 ± 13.9 74.2 ± 16.2 60.1 ± 9.8 53.9 ± 11.9
Pressure volume loop
  Ees (mmHg/ml) 1.17 ± 0.28 1.61 ± 0.77 0.96 ± 0.40 1.13 ± 0.27 1.04 ± 0.25 1.03 ± 0.50
  V0 (ml) −51.8 ± 43.0 −38.8 ± 36.5 −81.3 ± 38.9 −38.0 ± 44.1 −89.3 ± 22.2 −83.1 ± 43.9
  PRSW (mmHg) 34.5 ± 9.7 42.7 ± 18.6 30.3 ± 10.9 31.0 ± 9.1 53.0 ± 15.0* 48.2 ± 13.1**
Right heart catherization
  PCWP (mmHg) 13.2 ± 3.1 9.3 ± 2.3 11.0 ± 2.8 10.4 ± 1.9 7.0 ± 1.8* 10.7 ± 2.3**
SV (ml) 30.2 ± 4.0 39.2 ± 6.7* 31.8 ± 6.1** 36.6 ± 7.1 47.0 ± 4.0 50.1 ± 6.8*,**
Mean ± standard deviation, *P < 0.05 against control in post hoc test. **P < 0.05 by analysis of variance.
BW, body weight; dP/dt min, dP/dt minimum; E/A, mitral valve early (E) and late (A) ventricular filling velocity ratio; EDP, end diastolic pressure; EDV, end diastolic 
volume; Ees, end systolic elastance; ESV, end systolic volume; HR, heart rate; LA, left atrium; LVPmax, maximum left ventricular pressure; PCWP, pulmonary capillary 
wedge pressure; PRSW, preload-recruitable stroke work; SV, stroke volume.
Figure 2 Absolute changes of structural and functional parameters before and 2 months after gene transfer. Absolute changes of each animal 
are shown in dots. The bars represent mean ± SD. I-1c-treated pigs showed improved cardiac function after gene transfer with attenuated ventricular 
dilatation compared with saline treated pigs. Contractility index = (dP/dt maximum)/(P at dP/dt maximum−left ventricular end diastolic pressure); 
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by I-1c gene transfer, it is likely that the baseline scar size was 
already smaller in the low-dose group considering the baseline 
differences in various parameters. In contrast, baseline charac-
teristics of the high-dose and control groups were similar, and 
thus, the changes in the parameters would mainly derive from 
the difference in the treatment.
A novel vector for cardiac gene delivery
Recently, AAV vectors have emerged as a useful tool for therapeu-
tic gene transfer.5 Lack of pathogenicity and long-term expression 
are attractive features of AAV over other viral vectors for treat-
ing HF. Several AAV serotypes have been found, and advances 
in understanding of AAV biology unraveled that the diversity 
Figure 3 Heart weight and scar size 2 months after gene transfer. Scar size of the low-dose group was significantly smaller than saline-treated pigs. 
The bars represent mean ± SD. Representative pictures of cross-sectioned heart stained with triphenyl tetrazolium chloride are shown for different 














































Figure 4 I-1c mRNA expression in the heart, lung, and liver. Real-time quantitative polymerase chain reaction was performed on animals in the present 
study and AAV-9.I-1c-treated animals from ref. 11 (n = 6). (a) Relative I-1c mRNA levels in the heart (remote to the scar) from different groups. (b) Relative I-1c 
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in capsid surface topology is responsible for different tissue tro-
pism, antigenicity, and receptor affinity.7 Accordingly, attempts to 
produce novel vectors with clinically useful profiles were made 
by reengineering the capsid surface of AAV.8,25 Among the large 
numbers of chimeric AAV libraries generated by different labo-
ratories, some show significant promise in specific therapeutic 
purpose. For instance, muscular gene therapy using a chimeric 
AAV has already entered the clinical trial.26 In the present study, 
we chose a chimeric vector generated from AAV-2 and AAV-8, 
and demonstrated the promising efficacy of this novel vector for 
cardiac gene transfer. To characterize the gene distribution profile 
of BNP116 in the swine we compared the I-1c mRNA levels in 
multiple organs with pigs that have received AAV-9.I-1c. AAV-9 
has a natural cardiac tropism with lower affinity to transduce liver 
than other serotypes27 and provides efficient cardiac gene trans-
fer.28 In our study, BNP116 showed a similar or better expression 
profile compared to AAV-9 for detargeting major organs. Our 
distribution data in pigs are consistent with the results of Asokan 
et al.8 in mice who showed that cardiac and diaphragm muscles 
were transduced with high efficiency whereas low levels of vec-
tor genome copies were recovered from other major organs, such 
as brain, lung, and spleen. Importantly, cardiac tropism is a great 
advantage for clinical application, since it could minimize the 
extracardiac expression, which is especially important for genes 
that may affect major organ functions. Additionally, the total viral 
load to achieve sufficient gene expression may be reduced.
Another important advantage of capsid reengineering is an 
altered antigenic profile. The presence of NAbs against AAV as a 
result of previous exposure can significantly limit effective gene 
transfer.6 Because the high titers of NAb against AAV-1 was the 
major reason for study exclusion in CUPID trial,3 a different anti-
genic profile is a very attractive feature that can expand the can-
didates for clinical gene transfer. By reengineering the receptor 
footprint on the AAV capsid surface, BNP116 obtained a unique 
antigenic profile compared to the parental viruses.8 It has also been 
shown that BNP116 was only modestly neutralized after the expo-
sure to anti-AAV-2 serum, suggesting different antigenicity to the 
natural AAV serotypes. However, in contrast to our expectations, 
pigs had relatively high titers of NAb for BNP116 probably from 
infection with a virus with a similar capsid while they were raised 
together. Due to the high prevalence of NAb against BNP116 in pigs, 
we chose NAb titers < 1:8 as an inclusion criteria for the treatment 
group. While it needs further investigation whether this titer of NAb 
may alter the efficacy of cardiac gene transduction, lower efficacy 
of AAV-1.SERCA2a gene transfer in patients with only NAb = 1:229 
suggests that the inhibition of expression by NAb even at the low 
levels. Interestingly, despite the high NAb prevalence for BNP116 in 
pigs, the human sero prevalence was lower. Up to 20% of humans 
with NAb ≤ 1:2 is a promising advantage for future clinical applica-
tion. A possible option would be to screen the patients prior to gene 
therapy for NAb against multiple AAV serotypes including BNP116 
and choose the best vector considering the NAb titer and tropism, 
etc. While this vector may not be applicable to many of the patients, 
it can definitely broaden the candidates pool for AAV-mediated gene 
therapy.
In summary, I-1c overexpression using a novel chimeric AAV 
vector, BNP116, improved cardiac function in a swine model of 
ischemic HF. The optimal dose for BNP116.I-1c remains to be 
determined due to the difference in baseline characteristics in 
the low-dose group and relatively high NAb titers for BNP116 in 
the pig population. However, the positive results achieved with a 
simple delivery method in a clinically relevant model offers sig-
nificant promise for clinical translation.
MATERIALS AND METHODS
BNP116.I-1c construction. BNP116 vector packaging the cytomegalovirus-
driven sc-CMV.I-1c transgene cassette was produced and purified using 
previously published procedures.8,30 sc-CMV.I-1c is a self-complementary 
vector construct encoding a constitutively active and truncated form of I-1 
(first 65 amino acids), which is generated by using a 5′ primer homologous 
to the I-1 coding sequence with a flanking SalI site before the initiation 
start site (CGCCGCTGGTCGACCTGACCGGGAGCCATGGAG) and 
a 3′ primer (GTGGAGACATGCGGCCGCTCATGACAAGGTGGA) 
containing a Not-I site and translational stop site following the codon for 
amino acid 65. This was subcloned (SalI-NotI) into pBluescript SK II and 
amplified. The construct was then used to convert threonine-35 to aspar-
tic acid-35 with T7, T3, and a mutant primer engineered with appropriate 
nucleotide changes GGCAGGG(T3G)(C3T)GGGGCGGC. I-1c sequence 
analysis indicates that there are no alternative reading frames.
Animal protocols. The experimental protocols complied with the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals 
and standards of United States regulatory agencies. They were approved 
by the Institutional Animal Care and Use Committee of the Icahn School 
of Medicine at Mount Sinai. Yorkshire pigs (18–22 kg) were premedicated 
using intramuscular Telazol (8.0 mg/kg, Fort Dodge, IA). After the place-
ment of an intravenous line, animals were intubated and ventilated with 
100% oxygen. General anesthesia was maintained with intravenous pro-
pofol (8–10 mg/kg/hour) throughout the procedure. Electrocardiograms 
and pulse oximeter measurements were recorded at 5-minute intervals. 
Continuous monitoring with an intravenous saline infusion was main-
tained for a period of 30 minutes to stabilize the hemodynamic status. Then 
all animals underwent echocardiographic assessment, followed by hemo-
dynamic  measurement. All pigs received proximal left anterior descending 
coronary artery (LAD) balloon occlusion for 2 hours followed by reper-
fusion. Cardiac performance was evaluated at 1 month after MI and pigs 
were randomized to receive either high-dose BNP116.I-1c (3 × 1012 vg), 
low-dose BNP116.I-1c (1 × 1013 vg), or saline injection. Two months after 
the injection (3 months), cardiac performance was re-evaluated to deter-
mine the efficacy of gene transfer. Then the pigs were euthanized and tis-
sue samples were collected for histology and biodistribution analysis. Seven 
pigs received reporter gene injection to assess the cardiac transduction 
efficiency using BNP116.GFP (n = 4) and AAV-9.GFP (n = 3). These pigs 
Figure 5 Neutralizing antibody titers against BNP116 in pigs and 
humans. Percentage of patients and pigs with the indicated NAb titers, 
defined as the highest serum dilution resulting ≥50% inhibition of trans-
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were euthanized 1 month after the gene delivery and % green fluorescent 
cardiomyocytes were counted.
Cardiac performance assessment. A Philips iE-33 ultrasound system 
(Philips Medical Systems, Andover, MA) was used to acquire echocardio-
graphic data with a multifrequency imaging transducer. Complete Doppler 
transthoracic echocardiographic studies were performed. Images were 
recorded during end-expiratory breath-hold in the standard LV apical 
view. 3DE datasets were acquired from four to seven consecutive cardiac 
cycles using an R-wave-triggered mode. An average of three data sets were 
acquired per animal to ensure optimal data sets. Postacquisition image 
analyses were performed offline using a custom software package (Q-lab; 
Phillips Medical Systems) by two blinded investigators independently. 
LV volumes were calculated using 3D full-volume algorithms including a 
semiautomated border detection system. The endocardial detection accu-
racy was checked and optimized manually (Figure 1). Analysis was per-
formed in two different sequences and an average of two measurements 
were used for final data analyses. The methods for pressure measurement 
were previously described in detail.31 Briefly, percutaneous punctures were 
performed to establish the vascular access to the femoral artery and fem-
oral vein. Then, heparin (100 IU/kg intravenously) was administered to 
maintain an activated coagulation time of 200–300 seconds. A Swan-Ganz 
catheter (Edwards Lifesciences LLC, Irvine, CA) was advanced to the main 
pulmonary artery and pressure measurements were taken. Approximately 
0.25 × body weight (kg) ml of cold saline were injected into the infe-
rior vena cava to obtain cardiac output by the thermodilution method. 
Subsequently, an 11-Fr balloon catheter was advanced to the inferior vena 
cava for preload alterations. A 7-Fr, 12-electrode, dual-field conductance 
catheter (Millar Instruments, Houston, TX) was advanced into the LV 
for assessment of LV pressure–volume relationships. MPVS Ultra (Millar 
Instruments) was used to acquire analog data and convert it to digital data. 
Data analysis was performed using iox2 (Emka Technologies, Falls Church, 
VA). The conductance catheter gain factor α was calculated as the ratio of 
conductance-derived cardiac output to that measured by thermodilution. 
Parallel conductance was adjusted using the end diastolic volume obtained 
from 3DE. Contractility index was defined by the software as (dP/dt max)/
(pressure at dP/dt max−LV end diastolic pressure).23
MI creation. After cardiac performance evaluation was completed, a bolus 
of atropine (0.05 mg/kg) and amiodarone (1–3 mg/kg) were given intra-
venously or intramuscularly. A 1,000-ml saline bag mixed with atropine 
(0.1 mg/kg), amiodarone (3 mg/kg), and potassium acetate (20 mEq) was 
continuously infused at the rate of 300 ml/hour for the duration of the pro-
cedure. A 7-Fr hockey-stick catheter (Cordis, Miami, FL) was advanced 
to the left coronary artery. After the coronary angiogram, a 0.014-inch 
guide wire (Abbott, Park, IL) was advanced into the LAD and 8-mm-long, 
4.0-mm VOYAGER over-the-wire balloon (Abbott) was advanced to the 
proximal part of the coronary artery. The balloon was then inflated to 3–4 
atm for 120 minutes followed by reperfusion. In case of malignant arrhyth-
mia, direct current shock was applied immediately with continuous chest 
compression. After confirmation of hemodynamic stability, animals were 
allowed to recover. Intramuscular injections of nitroglycerine and furose-
mide were administered. Intravenous saline with amiodarone, atropine, 
and potassium acetate infusion was decreased to 50 ml/hour and was given 
overnight. The animals were housed in their cages, and examined daily for 
any signs of pain or distress.
Intracoronary gene delivery. Following the cardiac performance measure-
ments, 1 µg/kg/minute of nitroglycerin injection was started through an 
intravenous route until the end of the injection procedure to enhance the 
efficacy of gene transfer.32 The left coronary artery was cannulated with 
a 5Fr hockey stick catheter (CordisVista Brite Tip; Miami, FL) and two 
0.014-inch coronary guide wires (Abbott HI-TORQUE ADVANCE, Santa 
Clara, CA) were introduced in LAD and left circumflex coronary artery to 
fix the position of the catheter at the left main trunk. Fifteen milliliters of 
the virus or saline solution diluted 1:1 in blood were infused into the proxi-
mal part of the left main coronary artery at 1 ml/minute followed imme-
diately by a 5 ml flush of saline/blood solution at the same flow rate. Then 
the left coronary artery catheter is removed and the catheter was placed in 
the right coronary artery. Similarly, 5 ml of the diluted BNP116 or saline 
solution in blood 1:1 was infused into the right coronary artery at 1 ml/
minute followed immediately by a 5 ml flush. The visual guidance of the 
procedures are available in Ishikawa et al.33
In vitro neutralization assay for BNP116. 293T cells were plated on the 
day of the assay in Dulbecco's modified Eagle's medium with 1% peni-
cillin/streptomycin. The assay was performed 4–5 hours after plating. 
In a separate 96-well plate, stepwise twofold dilutions of pig sera were 
loaded with Dulbecco's modified Eagle's medium for pig samples and 
in Immunoglobulin Depleted Serum for human samples resulting in a 
total volume of 40 µl. Following the serum dilution, 40 µl of Dulbecco's 
modified Eagle's medium containing 8 × 108 vg of BNP116-CBALuc were 
added to each well. The mixture was incubated at 37 °C for 30 minutes 
and then 20 µl of the mixture was added per well in triplicate. Twenty-four 
hours later, the transduction efficiency was assessed by analyzing luciferase 
activity. The percentage of inhibition was calculated relative to no serum 
control. The luciferase assay was performed as previously described.34 
Briefly, the cells were lysed in the wells by adding equal volume of 2× 
lysis buffer (10 mmol/l Tris–hydrochloride pH 8.0, 150 mmol/l NaCl, 1% 
(wt/vol) NP40, 10 mmol/l dithiothreitol). Twenty microliters of the cell 
lysate were then mixed with 100 µl of luciferase assay buffer (25 mmol/l 
Tricine–hydrochloride pH 7.8, 5 mmol/l magnesium sulfate, 0.5 mmol/l 
ethylenediaminetetraacetic acid (pH 8.0), 3.3 mmol/l dithiothreitol, 0.5 
mmol/l ATP pH ~7–8 (A26209; Sigma-Aldrich, St Louis, MO), 1 mg/ml 
bovine serum albumin, 0.05 mg/ml D-luciferin (cat. no.: LUCK-100; Gold 
Biotechnology, St Louis, MO), 0.05 mmol/l CoA (cat. no.: 13787, United 
States Biological, Swampscott, MA) and the luminescence was read in a 
luminescence counter (Microbeta Trilux 1450 LSC and Luminescence 
Counter; Perkin Elmer, Carlsbad, CA). The titer of neutralizing antibody 
was categorized into <1:2, =1:2, =1:4, = 1:8, and >1:8, reflecting the highest 
dilution factor to exhibit ≥50% inhibition of transduction compared to no 
serum controls. These dilution factors are shown in a circular graph repre-
senting the percentage of investigated population. The protocol for testing 
NAb prevalence in human serum samples was reviewed and approved by 
the local Institutional Review Board.
Postmortem histology. Hearts were explanted, weighed, and sectioned 
into six slices. One layer from the papillary muscle level was stored 
for biodistribution studies. Additionally, liver, lung, brain, and kidney 
were collected to assess off-target effect. The remainder of the heart was 
stained with triphenyl-tetrazolium chloride to delineate the scar area 
from viable tissue and the size of the infarction was assessed by digital 
planimetry.
Real-time quantitative polymerase chain reaction (qPCR) detection 
of I-1C mRNA. Total RNA was isolated with TRIzol reagent (Invitrogen, 
Carlsbad, CA) followed by DNase I treatment (Qiagen, Valencia, CA). 
Total RNA was reverse transcribed using the high-capacity cDNA Reverse 
Transcription kit (Applied Biosystems, ABI) according to the manufac-
turer’s protocol. Quantitative PCR reactions were performed with Power 
SYBR Green Master Mix using an ABI Prism 7500 Real Time PCR System. 
The real-time qPCR assay detects a 125 bp sequence unique to I-1c and the 
number of copies of I-1c was quantified using serial dilutions of a plasmid 
containing the target sequences as standards. Primers for the I-1c were 
designed with the Primer Express software based on the human protein 
sequence (NP 006732.3; forward: CGTGCCCCTGCTGGAA; reverse: 
TCCGGTCCTCGTCGATCTC). Because relatively high numbers of 
cycles were required for detection, accurate quantification of the vector 
genomes was challenging. Quantitation of the I-1c mRNA detected in the 
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lung and liver, relative to the heart sample remote from the scar region, 
was calculated in the same animal to evaluate the off-target transductions. 
Samples of AAV-9.I-1c gene transferred animals11 were used for the com-
parison to BNP116.I-1c.
Statistical analysis. Data are expressed as means ± standard deviations. 
Study sample size was determined by using an α value of 0.05, a power of 
80% to detect a 6% absolute increase of LVEF in the assumption of 3.5% 
standard deviation with 1 control per treatment animal. Comparison 
between before MI and 1 month after MI data was performed by paired 
t-tests. Comparisons between the three groups were performed by analysis 
of variance at baseline and for the absolute changes overtime, followed by 
Tukey post hoc test. In the presence of statistically significant differences 
in the analysis of variance test of baseline comparisons, the change scores 
between the time points were adjusted by the baseline values. Intra- and 
interclass correlation coefficients were analyzed to assess the agreement of 
two repeated measurements for 3DE volume analysis. A P value of <0.05 
was considered statistically significant.
SUPPLEMENTARY MATERIAL
Representative movies of 3DE analyses from each group are provided 
in mov. files.
Figure S1. Hematoxylin & eosin staining of organs.
Figure S2. Color images of heart cross sections (Figure 3).
Movie S1. Control.
Movie S2. High-dose BNP116.I-1c.
Movie S3. Low-dose BNP116.I-1c.
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